Inclusion Criteria

        Subjects are eligible to be included in the study only if all of the following inclusion
        criteria and none of the exclusion criteria apply.

          1. Signed and dated informed consent. For inclusion in the optional pharmacogenetic
             research, patients must provide informed consent for the genetic sampling and
             analyses.

          2. ≥ 18 years of age.

          3. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

          4. Minimum life expectancy of 12 weeks

          5. Part A of the study will include patients that have histological confirmation of a
             solid malignancy [other than Hepatocellular Carcinoma (HCC)] that is refractory to
             standard therapy or for which no standard of care regimen currently exists.

          6. Part D of the study will include patients with histological confirmation of a solid
             malignancy (other than HCC) that are refractory to standard therapy of for which no
             standard of care regimen currently exists.

          7. Willing to undergo mandatory biopsy at screening and on treatment. Part A only: the
             first 3 subjects in each arm are exempt from this requirement. Patients in Part D are
             exempt from this biopsy requirement.

          8. At least one lesion, not previously irradiated, that can be accurately measured at
             baseline as ≥10 mm in the longest diameter (except lymph nodes that must have short
             axis ≥15 mm) with computerised tomography (CT) or magnetic resonance imaging (MRI)
             that is suitable for accurate repeated measurements.

          9. Females should be using adequate contraceptive measures, should not be breast feeding,
             and must have a negative pregnancy test prior to start of dosing if of child-bearing
             potential or must have evidence of non-child-bearing potential by fulfilling one of
             the following criteria at screening:

               -  Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least
                  12 months following cessation of all exogenous hormonal treatments

               -  Women under 50 years old would be considered postmenopausal if they have been
                  amenorrheic for 12 months or more following cessation of exogenous hormonal
                  treatments and with luteinising hormone and follicle-stimulating hormone levels
                  in the post-menopausal range for the institution

               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
                  oophorectomy, or bilateral salpingectomy, but not tubal ligation.

         10. Male patients must be surgically sterile or using an acceptable method of
             contraception (defined as barrier methods in conjunction with spermicides) for the
             duration of the study (from the time they sign consent) and for 20 weeks after the
             last dose of study treatments.

        Exclusion Criteria

        Patients should not enter the study if any of the following exclusion criteria are
        fulfilled.

          1. Involvement in the planning and/or conduct of the study (applies to AstraZeneca and/or
             Sarah Cannon Development Innovations staff and/or staff at the study site).

          2. Previous enrolment in the present study.

          3. Herbal preparations are not allowed throughout the study. These herbal medications
             include but are not limited to St. John's wort, kava, ephedra (mahung), gingko biloba,
             dehydroepiandrosterone (DHEA), yohimbe, saw palmetto and ginseng. Patients should stop
             using herbal medications 7 days prior to the first dose of study treatment.

          4. Brain metastases or spinal cord compression unless asymptomatic and not requiring
             steroids for at least 14 days prior to start of study treatment.

          5. With the exception of alopecia and haemoglobin (Hb) ≥ 9 mg/dL and < 10 mg/dL, any
             unresolved toxicities from prior therapy CTCAE Grade > 1 at the time of starting study
             treatment.

          6. Active interstitial lung disease (ILD)/pneumonitis or a prior history of
             ILD/pneumonitis requiring treatment with steroids.

          7. Patients receiving any concurrent chemotherapy, radiotherapy, immunotherapy, or
             biologic, or hormonal therapy for cancer.

               -  Concurrent use of hormones for noncancer-related conditions (e.g., insulin for
                  diabetes and hormone replacement therapy) is acceptable. The dose of systemic
                  corticosteroids must not exceed 10 mg of prednisone equivalent.

               -  Patients in Part A and Part D with radically-treated prostate cancer may continue
                  androgen deprivation therapy (ADT).

          8. Patients must have completed any previous cancer-related treatments before enrolment.
             The following intervals between the end of the prior treatment and first dose of study
             drug must be observed:

               -  Port-a-cath placement: no waiting is required

               -  Minor surgical procedures (as defined by the Medical Monitor): 7 postoperative
                  days

               -  Major surgery (as defined by the Medical Monitor): ≥4 weeks

               -  Radiotherapy: ≥4 weeks (patients who receive palliative radiation for nontarget
                  tumour lesions need not be subjected to this washout period and can be enrolled
                  immediately)

               -  Chemotherapy: ≥ 21 days or 5 half-lives (whichever is longer) from the first dose
                  of study drug

               -  Immunotherapy and/or anticancer therapy with agents including mAbs ≥4 weeks

               -  Current or prior use of immunosuppressive medication within 14 days before first
                  dose of durvalumab The following are exceptions to this criterion:

                    -  Use of intranasal, inhaled, topical corticosteroids, local steroid
                       injections (e.g., intra articular injections)

                    -  Systemic corticosteroids at physiologic doses below 10 mg/day of prednisone
                       or equivalent is permitted

                    -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan
                       premedication) are permitted

          9. For Part A and Part D patients who have received more than 3 prior cytoreductive
             chemotherapy regimens.

         10. Has active or prior documented autoimmune disease within the past 2 years with the
             exceptions of vitiligo, Graves' Disease, and/or psoriasis not requiring systemic
             treatment

         11. Has active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis)

         12. Has a history of primary immunodeficiency

         13. Has undergone an organ transplant that requires use of immunosuppressive treatment

         14. Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (QTc) calculated using Fridericia's formula
                  (QTcF) of >450 msec for males and >470 msec for females obtained from 3
                  electrocardiograms (ECGs) taken over 5 minutes

               -  Any clinically important abnormalities in rhythm, conduction or morphology of a
                  resting ECG, e.g., complete left bundle branch block, third degree heart block,
                  that in the opinion of the Investigator renders the patient unsuitable for
                  participation in the study

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, hypokalaemia, congenital long QT syndrome, family
                  history of long QT syndrome or unexplained sudden death under 40 years-of-age

               -  Any concomitant medication with known or possible risk of prolonging the QT
                  interval.

         15. Inadequate organ and marrow function as demonstrated by any of the following
             laboratory values. Transfusions intended to elevate any parameters below solely for
             the intent of meeting study eligibility are not permitted.

               -  Leukocytes <3.0 x 10(exp 9)/L

               -  Absolute neutrophil count <1.5 x 10(exp 9)/L

               -  Platelet count <100 x 10(exp 9)/L

               -  Haemoglobin <90 g/L

               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the
                  upper limit of normal (ULN) if no demonstrable liver metastases or >5 times ULN
                  in the presence of liver metastases

               -  Total bilirubin >1.5 times ULN if no liver metastases or 3 times ULN in the
                  presence of liver metastases or documented Gilbert's Syndrome (unconjugated
                  hyperbilirubinaemia)

               -  Creatinine outside normal limits OR, if creatinine outside normal limits, a
                  creatinine clearance <60 mL/min (measured by 24-hour urine collection or
                  calculated by Cockcroft and Gault equation (Cockcroft and Gault 1976).

         16. Has a history of allergic reactions attributed to the study treatments (AZD9150 or
             durvalumab), assigned chemotherapy agents, their compounds, or agents of similar
             chemical or biologic composition (e.g., antibody therapeutics)

         17. Suffers from a comorbidity that in the opinion of the Investigator or Medical Monitor
             renders the patient unsuitable for participation in the study. Such comorbidity may
             include, but is not limited to, uncontrolled intercurrent illness such as active
             infection, severe active peptic ulcer disease or gastritis, myocardial infarction
             within 6 months before entry, congestive heart failure, symptomatic congestive heart
             failure, active cardiomyopathy, unstable angina pectoris, cardiac arrhythmia,
             uncontrolled hypertension, or psychiatric illness/social situations that would limit
             compliance with study requirements.

         18. As judged by the Investigator, has any evidence of severe or uncontrolled diseases, or
             has an active viral infection of human immunodeficiency virus (HIV), human papilloma
             virus (HPV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV)].

         19. Active infection including tuberculosis (clinical evaluation that included clinical
             history, physical examination and radiographic findings, and tuberculosis testing in
             line with local practice).

         20. Has received a live attenuated vaccine within 28 days before the first dose of study
             drug

         21. Judgment by the Investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions, and
             requirements.